213 related articles for article (PubMed ID: 8908384)
1. Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation.
Gerstein HC; Bosch J; Pogue J; Taylor DW; Zinman B; Yusuf S
Diabetes Care; 1996 Nov; 19(11):1225-8. PubMed ID: 8908384
[TBL] [Abstract][Full Text] [Related]
2. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.
Lancet; 2000 Jan; 355(9200):253-9. PubMed ID: 10675071
[TBL] [Abstract][Full Text] [Related]
3. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.
Gerstein HC
Diabetes Metab Res Rev; 2002; 18 Suppl 3():S82-5. PubMed ID: 12324991
[TBL] [Abstract][Full Text] [Related]
4. The HOPE Study (Heart Outcomes Prevention Evaluation).
Sleight P
J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
[TBL] [Abstract][Full Text] [Related]
5. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).
Marre M; Lievre M; Chatellier G; Mann JF; Passa P; Ménard J;
BMJ; 2004 Feb; 328(7438):495. PubMed ID: 14960504
[TBL] [Abstract][Full Text] [Related]
6. Diabetes and the HOPE study: implications for macrovascular and microvascular disease.
Gerstein HC
Int J Clin Pract Suppl; 2001 Jan; (117):8-12. PubMed ID: 11715357
[TBL] [Abstract][Full Text] [Related]
7. The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not.
Hoogwerf BJ; Young JB
Cleve Clin J Med; 2000 Apr; 67(4):287-93. PubMed ID: 10780101
[TBL] [Abstract][Full Text] [Related]
8. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.
Can J Cardiol; 1996 Feb; 12(2):127-37. PubMed ID: 8605634
[TBL] [Abstract][Full Text] [Related]
9. HOPE for all people with diabetes? Heart Outcomes Prevention Evaluation.
Marshall SM
Diabet Med; 2000 Sep; 17 Suppl 2():9-10. PubMed ID: 11048826
[No Abstract] [Full Text] [Related]
10. Why were the results of the Heart Outcomes Prevention Evaluation (HOPE) trial so astounding?
Mancini GB; Stewart DJ
Can J Cardiol; 2001 May; 17 Suppl A():15A-7A. PubMed ID: 11381289
[TBL] [Abstract][Full Text] [Related]
11. Effect of angiotensin-converting enzyme inhibition on survival in 3773 Chinese type 2 diabetic patients.
So WY; Ozaki R; Chan NN; Tong PC; Ho CS; Lam CW; Ko GT; Chow CC; Chan WB; Ma RC; Chan JC
Hypertension; 2004 Sep; 44(3):294-9. PubMed ID: 15249544
[TBL] [Abstract][Full Text] [Related]
12. Preventing end-stage renal disease.
Mogensen CE
Diabet Med; 1998; 15 Suppl 4():S51-6. PubMed ID: 9868993
[TBL] [Abstract][Full Text] [Related]
13. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy.
Lonn E; Yusuf S; Hoogwerf B; Pogue J; Yi Q; Zinman B; Bosch J; Dagenais G; Mann JF; Gerstein HC; ;
Diabetes Care; 2002 Nov; 25(11):1919-27. PubMed ID: 12401733
[TBL] [Abstract][Full Text] [Related]
14. The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. DIABHYCAR Study Group.
Lièvre M; Marre M; Chatellier G; Plouin P; Réglier J; Richardson L; Bugnard F; Vasmant D
Control Clin Trials; 2000 Aug; 21(4):383-96. PubMed ID: 10913814
[TBL] [Abstract][Full Text] [Related]
15. What should the role of ACE inhibitors be in the treatment of diabetes? Lessons from HOPE and MICRO-HOPE.
Heinig RE
Diabetes Obes Metab; 2002 Jan; 4 Suppl 1():S19-25. PubMed ID: 11843951
[TBL] [Abstract][Full Text] [Related]
16. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria.
Ahmad J; Siddiqui MA; Ahmad H
Diabetes Care; 1997 Oct; 20(10):1576-81. PubMed ID: 9314638
[TBL] [Abstract][Full Text] [Related]
17. Modifying the natural history of atherosclerosis: the SECURE trial.
Lonn E
Int J Clin Pract Suppl; 2001 Jan; (117):13-8. PubMed ID: 11715353
[TBL] [Abstract][Full Text] [Related]
18. Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study.
Mann JF; Gerstein HC; Yi QL; Franke J; Lonn EM; Hoogwerf BJ; Rashkow A; Yusuf S;
Am J Kidney Dis; 2003 Nov; 42(5):936-42. PubMed ID: 14582037
[TBL] [Abstract][Full Text] [Related]
19. Microalbuminuria: a marker to increased renal and cardiovascular risk in diabetes mellitus.
McKenna K; Thompson C
Scott Med J; 1997 Aug; 42(4):99-104. PubMed ID: 9507584
[TBL] [Abstract][Full Text] [Related]
20. Study design and baseline characteristics of the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E: SECURE.
Lonn EM; Yusuf S; Doris CI; Sabine MJ; Dzavik V; Hutchison K; Riley WA; Tucker J; Pogue J; Taylor W
Am J Cardiol; 1996 Oct; 78(8):914-9. PubMed ID: 8888665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
